Atomo NewsGet the app

Get the latest Science News and Discoveries

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC


None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of NSCLC

NSCLC

Photo of Line

Line

Photo of EGFR

EGFR

Related news:

News photo

Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC

News photo

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

News photo

In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC

« Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC
Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC »